close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

14.66 -0.06 (-0.41%)
Streaming Delayed Price Updated: 10:15 AM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength ↗
Hutchmed forecasts 2025 oncology revenue of $350–$450 million after a strong 65% growth in 2024, driven by Fruzaqla sales and new regulatory approvals in China. 
Via Benzinga
News headline image
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
65% oncology products revenue growth drove profitable operation and supported new ATTC platform 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Earnings Scheduled For March 19, 2025 ↗
 
Via Benzinga
News headline image
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2024 Final Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million ↗
Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including clinical trials by 2025. 
Via Benzinga
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today